These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 25771943

  • 21. [Pneumocystis pneumonia in patients with immunosuppression other than HIV infection].
    Adler D, Chenivesse C, Similowski T, Soccal PM.
    Rev Med Suisse; 2008 Nov 19; 4(180):2525-6, 2528-30. PubMed ID: 19127897
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
    Schmajuk G, Jafri K, Evans M, Shiboski S, Gianfrancesco M, Izadi Z, Patterson SL, Aggarwal I, Sarkar U, Dudley RA, Yazdany J.
    Semin Arthritis Rheum; 2019 Jun 19; 48(6):1087-1092. PubMed ID: 30449650
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
    Yang H, Pang L, Hu X, Wang W, Xu B, Zhang X, Liu L.
    J Pharm Pharm Sci; 2021 Jun 19; 24():220-226. PubMed ID: 33956598
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
    Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D.
    Chest; 2020 Dec 19; 158(6):2323-2332. PubMed ID: 32502592
    [Abstract] [Full Text] [Related]

  • 28. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
    Proudfoot R, Phillips B, Wilne S.
    J Pediatr Hematol Oncol; 2017 Apr 19; 39(3):194-202. PubMed ID: 28267082
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for Pneumocystis jirovecii pneumonia in pediatric oncology patients.
    Awad M, Sierra CM, Mesghali E, Bahjri K.
    J Oncol Pharm Pract; 2021 Dec 19; 27(8):1936-1939. PubMed ID: 33307970
    [Abstract] [Full Text] [Related]

  • 31. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
    Tu GW, Ju MJ, Xu M, Rong RM, He YZ, Xue ZG, Zhu TY, Luo Z.
    Nephrology (Carlton); 2013 Nov 19; 18(11):736-42. PubMed ID: 24571744
    [Abstract] [Full Text] [Related]

  • 32. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK, Foisy MM, Hughes CA.
    Ann Pharmacother; 2015 Dec 19; 49(12):1343-8. PubMed ID: 26358129
    [Abstract] [Full Text] [Related]

  • 33. [Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia].
    Enomoto T, Azuma A, Matsumoto A, Nei T, Hiramatsu K, Abe S, Usuki J, Kudoh S.
    Nihon Kokyuki Gakkai Zasshi; 2005 Dec 19; 43(12):725-30. PubMed ID: 16457333
    [Abstract] [Full Text] [Related]

  • 34. Critical appraisal of the quality and content of clinical practice guidelines for pneumocystis jiroveci pneumonia (PJP) prophylaxis using the AGREE II instrument.
    Yu Y, Yang H, Yu X, Hu X, Wang W, Yang X, Liu H, Ren L, Zhang X, Feng X, Liu L.
    J Clin Pharm Ther; 2020 Dec 19; 45(6):1325-1333. PubMed ID: 32710453
    [Abstract] [Full Text] [Related]

  • 35. When to consider Pneumocystis jirovecii prophylaxis in HIV-negative patients.
    Dameron M, Horowitz M, Gupta N, Abi Hatem N.
    JAAPA; 2021 Feb 01; 34(2):24-26. PubMed ID: 33470717
    [Abstract] [Full Text] [Related]

  • 36. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
    Okafor PN, Wasan SK, Farraye FA.
    Inflamm Bowel Dis; 2013 Feb 01; 19(4):812-7. PubMed ID: 23435401
    [Abstract] [Full Text] [Related]

  • 37. [Pneumocystosis in non-HIV-infected immunocompromised patients].
    Fillâtre P, Revest M, Belaz S, Robert-Gangneux F, Zahar JR, Roblot F, Tattevin P.
    Rev Med Interne; 2016 May 01; 37(5):327-36. PubMed ID: 26644039
    [Abstract] [Full Text] [Related]

  • 38. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM, Galal A, Richardson CL, Sutton SH, Barr VO, Patel N, Mitchell P, Stosor V.
    Transpl Infect Dis; 2017 Dec 01; 19(6):. PubMed ID: 28833985
    [Abstract] [Full Text] [Related]

  • 39. A heart transplant recipient lost due to Pneumocystis jiroveci pneumonia under trimethoprim-sulfamethoxazole prophylaxis: case report.
    Celik T, Gedik E, Kayabas U, Bayindir Y, Gulbas G, Firat AK, Togal T.
    Exp Clin Transplant; 2010 Dec 01; 8(4):325-8. PubMed ID: 21143101
    [Abstract] [Full Text] [Related]

  • 40. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R, Bemelman FJ, Hodiamont CJ, Idu MM, Ten Berge IJ, Geerlings SE.
    BMC Infect Dis; 2016 Feb 25; 16():90. PubMed ID: 26912326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.